The Board of Directors at their meeting held on 12/August/2026 approved to acquire 3,000 equity shares (30.00% of paid up capital) of Sudarshan Maven Pharma Private Limited. Upon acqusition, ....

$UDIRSHIII IIIDUIIRIEN LID Head Office : 301, Aura Biplex, Premium Retail Premises, 7, S.V. Hoad, Borivall (West), fi/umbai - 400092. E-mail : compliance@sudarshanpharma.com Website: www.sudarshanpharma.com BoardLine: +91-22-42221111 i 43331111 142221116 (100line)rQ11t1 :151496X,/H2008P1C184997 Date: 13th August 2026 s P I L/CS/SE/ 2O26-2O27J 43 The Listing Depaftment BSE Limited BSE Scrip Code: 543828 Phiroze JeejeebhoY Towers, BSE Trading SYmbol: SUDARSHAN Dalal Street, Mumbai - 400 001 lSlN: lNE00TV01023 S Ru eb fr l Dn it sim cla ot sio un re f o pr u a rsp up ar no tv a tl oto Ra ecq gu ui lr ae t is oh na r 3e 0s o of fs u thda er s sh Ean B l M (La iv se tin n gP h oa brm liga a P tioriv na st e A L nim d it Ded isclosure Requirements) Regulations, 2015 Dear Sir / Madam, pursuant to Regulation 30 of sEBl (Listing obligation And Disclosure Requirements) Regulations' 201-5 (,SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have at their meeting held on 12th August 2026,inlerl-alia, approved to acquire 3'000 equity shares of Rs'10/- each of Sudarshan Maven Pharma Private Limited ('sudarshan Maven') (ClN: u21001tvlH2 024PTC431,150), subsidiary of the company, equivalent to 30'00% of the paid-up equity share capital of Sudarshan Maven. Upon completion of the acquisition, Sudarshan tVlaven would become a wholly-owned subsidiary of the Company' The details as required under the sEBl Listing Regulations read with sEBl circular SEBt/HO/CFO/poOZ/Cin lPlO1,55 dated 11th November 2024 are given in Annexure-A' You are requested to take the same on record' Thanks & Regards, Yours faithfullY, For, Sudarshan Pharma lndu W a. HemalMehta Chairman & Managing Di Regd. Off. : 301, Aura Biplex, Above Kalyan Jewellers, $.V Road, Borivali (West), Mumbai - 400092. PHIRIII XUD[RgHNil IIIDUIIRIEX LID Head Office : 301, Aura Biplex, Premium Retail Premises, 7, S.V. Fload, Borivali (West), [/umbai - 400092. E-mail : compliance@sudarshanpharma.com Website: www.sudarshanpharma.com Board Line : +91-22-422211 1 1 / 4333'1 111 I 422211 16 (100 line) r Q1p : 151496h/1H2008P1C184997 Annexure-A. D Ree gta ui lr as ti or ne sq u ,zir xe Ld | ru en ad de r w R tthe g su rr Ba lt i co in rc 3 ul0 a ro sf rt sh r/e H oS /E cB rD' ( /L pi os Dtin 2g /C o lRbr ig lPa t li oo tn 5s 5 A dan td e dD 1is 1c tr ho s Nu or ve e R me bq eu ri r 2e 0m 2e 4n t as r) e given below SL Details to be Provided lnformation L Name of the target entity, details in Name: Sudarshan Maven Pharma Private Limited brief such as size, etc. (As on 31't March 2026) Authorised Share Capital: Rs'25,00,000/- Paid Up Share CaPital: Rs.1,00,000/- Revenue from OPerations: Nil 2 Whether the acquisition would fall No. within related party transactions and whether the Promoter I The acquisition would not fall within the related party promoter group / grouP comPanies transactions. have any interest in the entity being acquired? lf Yes, nature of the interest and details thereof and whether the same is done at 'arm's length' 3 tndustry to which the entitY being fS ou rd mar us lh aa tn io M n,a v pe rn o ci es s P sr ii nm ga , ri dly e ve en lg oa pg med enin t, th ime pm oa rn tu ' fa ec xt pu ore rt, ' acquired belongs. distribution and trading of pharmaceutical and healthcare products 4 OUjects and effects of acquisition Sudarshan Maven is in similar line ofbusiness activities as of the (includin[ but lot limited to, CompanY disclosure of reasons for acquisition of target entitY, if its business is Upon completion of acquisition, Sudarshan Maven would outside the main line of business of become a wholly-owned subsidiary of the Company' the listed entitY) 5 Brief details of governmentaI or any Not Applicable regulatory approvals "required for the acquisition lndicative time period for 3l-'t December 2026 6 ma com etion of the uisition 7 Nature of Consideration whether To be subscribed in cash c Cash consideration or share swaP and details of the same Regd. Off. : 301, Aura Biplex, Above Kalyan Jewellers, $.V. Road, Borivali {West), Mumbai - 400092 XUDIRXHIII PHIRIIA IIIDUXIRIEX Head Office : 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), tvlumbai - 400092. E-mail : compliance@sudarshanpharrna.com Website: urww.sudarshanpharma.com Board l-ine: +91'22'42221111 14333't111 142221116 (100line)r911 :151496t\IH2008PlC184997 8 Cost of acquisition or the price at Cost of acquisition shall be based uPon u on which the shares are acquired Maven 9 P ace qrc ue irn et da g ae do f a nre uh mo bl ed rin og c so hn at rr eo sl 3 sh,0 a0 re0 ce aq pu itit aY s oh a Sr ue ds o rsf aR ns . M10 a/ v- ee na 'ch (gO.OO'l, of the Paid-uP acquired 10 Brief background about the entitY Briefbackground: a oc fq u bir ue sd i nin e ste sr m as c qo uf irp ero dd , u dc ats t/ e li n oe f Sudarshan Maven Pharma Private Limited was incorporated on incorporation, history of last 3 years 27th Augusl2OZ4. turnover, countrY in which the a anc yq u oi tr he ed r e sin gt nit iY fic ah na ts inP fr oe rs me an tc ioe na n (id n S f dou isrd m ta rir bus ulh a ta it on io n M n a,a nv p de r n o t c ri aes ds p s inr ii n gm g oa , r fi d ly pe hve aen rg l moa p ag ce m ed e u i tnn ict ' at h li me a npm doa r hn t eu ' afa e ltc hxt cpu aor re r et' ' brief) products Sudarshan Maven has not yet commenced its commercial activities Last 2 years' turnover details: (Amount in Lakhs) FinancialYear 2025-26 2024-25 For, Sudarshan Pharma lnd Limited tu a c(g :' Hemal Mehta Chairman & Manag Regd. Off, I 30'1, Aura Biplex, Above Kalyan Jewellers, $,V. Road, Borivali (West), Mumbai - 400092,